National Research Corp. (NASDAQ:NRCIB) CEO Michael D. Hays sold 3,533 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $16.19, for a total transaction of $57,199.27. Following the completion of the sale, the chief executive officer now directly owns 6,467,744 shares in the company, valued at $104,712,775.36. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
National Research Corp. (NASDAQ:NRCIB) opened at 35.02 on Monday. National Research Corp. has a 1-year low of $31.36 and a 1-year high of $44.60. The firm has a market capitalization of $848.22 million, a PE ratio of 43.02 and a beta of 0.28. The company has a 50 day moving average of $34.03 and a 200 day moving average of $35.17.
National Research Corp. (NASDAQ:NRCIB) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $0.18 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.18. National Research Corp. had a net margin of 18.75% and a return on equity of 33.74%. Analysts forecast that National Research Corp. will post $0.82 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 14th. Shareholders of record on Friday, September 30th will be issued a dividend of $0.48 per share. The ex-dividend date is Wednesday, September 28th. This represents a $1.92 dividend on an annualized basis and a yield of 5.48%. National Research Corp.’s payout ratio is currently 408.52%.
A hedge fund recently bought a new stake in National Research Corp. stock. Willis Investment Counsel acquired a new position in National Research Corp. (NASDAQ:NRCIB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 13,329 shares of the company’s stock, valued at approximately $442,000. Willis Investment Counsel owned approximately 0.06% of National Research Corp. at the end of the most recent reporting period. 2.90% of the stock is owned by institutional investors and hedge funds.
Separately, Zacks Investment Research upgraded shares of National Research Corp. from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Friday, August 12th.
National Research Corp. is a business services company in the Health Care Services industry.
Receive News & Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.